Summary of Nurix Therapeutics (NRIX) Investor Call - June 12, 2025 Company Overview - **Company**: Nurix Therapeutics - **Product**: Bexabrutinib (NRX-5948) - **Focus**: Treatment of Chronic Lymphocytic Leukemia (CLL) and Waldenstrom's Macroglobulinemia Key Points Clinical Updates - **Clinical Trials**: Updates were provided on the phase one trials of Bexabrutinib, particularly focusing on patients with relapsed refractory CLL and Waldenstrom's Macroglobulinemia [2][3][4] - **Efficacy**: The overall response rate (ORR) for Bexabrutinib in relapsed refractory CLL is reported at **80.9%**, with a complete response (CR) in one patient and a partial response (PR) in **78.7%** of patients [13][20] - **Patient Demographics**: The median age of patients in the CLL study is **68.5 years**, with a heavily pretreated population having a median of **four prior lines of therapy** [9][19] - **Safety Profile**: Bexabrutinib has shown a favorable safety profile with no new safety signals reported. The most common adverse events were minor infections, which are common in CLL patients [12][27] Market Potential - **Market Size**: The BTK inhibitor market is projected to grow from **$9 billion** in 2024 to over **$15 billion** by 2028, indicating a substantial opportunity for Bexabrutinib [38] - **Patient Population**: Over **55,000 patients** start therapy for CLL each year, with significant numbers initiating therapy in various lines of treatment [39][40] Regulatory Progress - **Fast Track Designation**: Bexabrutinib received fast track designation from the FDA, supporting an accelerated pathway for registration [31] - **Future Trials**: Plans for pivotal trials in 2025 were discussed, including a single-arm phase two study for relapsed refractory CLL patients and combination trials with BCL-2 inhibitors [33][34] Competitive Landscape - **Positioning**: Bexabrutinib is positioned as a best-in-class BTK degrader, with the potential to address unmet medical needs in CLL and Waldenstrom's [30][37] - **CNS Activity**: The drug has shown promising CNS activity, which may differentiate it from competitors that exclude patients with CNS lesions [91][98] Additional Insights - **Patient Response**: The median time to response for patients is reported at **1.9 months**, with ongoing monitoring for deepening responses over time [16][20] - **Combination Therapy**: There is a focus on combination therapies as the emerging standard of care, with plans to explore this in future studies [104] Conclusion - **Future Outlook**: Nurix Therapeutics is optimistic about the potential of Bexabrutinib to shape the future standard of care in CLL and Waldenstrom's Macroglobulinemia, with ongoing clinical trials and regulatory discussions paving the way for its market entry [34][43]

Summary of Nurix Therapeutics (NRIX) Conference Call Company Overview - **Company**: Nurix Therapeutics (NRIX) - **Focus**: Development of degrader therapies, particularly in oncology and autoimmune diseases Key Points Product Development and Clinical Trials - **Bexdeg (NRX-5948)**: A degrader therapy currently in phase 1a trials, with updates expected by the end of the year for phase 1b data [6][10] - **Regulatory Updates**: A formal update on pivotal studies is anticipated mid-year, including feedback from the FDA regarding study design and dosing [9][10] - **Phase 2 and Phase 3 Studies**: Plans for a single-arm phase 2 study in CLL and a confirmatory randomized phase 3 study are in development, with details to be disclosed later this year [10][11] - **Waldenstrom's Group**: Approximately 80% response rate observed, similar to CLL, indicating strong activity across various indications [23][24] Strategic Focus - **Prioritization**: CLL is the primary focus, with resources allocated to maximize impact in this area [24][25] - **BTK Degrader Mechanism**: The rationale for using a BTK degrader includes addressing severe life-threatening conditions with high unmet medical needs, aiming for rapid data readouts and targeting large markets [27][30] Safety and Efficacy - **Safety Profile**: The degrader mechanism may offer a better safety profile compared to traditional inhibitors, with lower required drug levels and reduced off-target effects [34][35] - **Efficacy**: Degradation of the target protein may provide a more comprehensive therapeutic effect by eliminating both enzymatic and scaffolding functions of the protein [36] Partnerships and Collaborations - **Sanofi Partnership**: Nurix has partnered with Sanofi for the development of NX3911, a novel STAT6 degrader, with Sanofi funding IND enabling studies and phase 1 trials [46][47] - **Gilead Collaboration**: An agreement with Gilead for the Abreq4 degrader, with updates expected as they move into healthy volunteer studies [64] Pipeline Updates - **Other Pipeline Candidates**: Updates on additional candidates, including a sibyl inhibitor (1607) and another candidate (2127), are expected, with the sibyl inhibitor showing promise in a phase 1a trial across 11 solid tumors [68][69] Market Position and Future Outlook - **Market Opportunity**: The company is positioned to capitalize on a large autoimmune landscape, with potential for multiple successful products in the market [62][63] - **Competitive Edge**: Nurix aims to be best in class with its programs, leveraging its partnerships and innovative approaches to drug development [61][62] Additional Insights - **Enrollment and Data Disclosure**: Enrollment rates for ongoing studies will dictate the timing of data disclosures, particularly for the CLL cohort with warm autoimmune hemolytic anemia [38][39] - **Regulatory Strategy**: The company is focused on designing studies that are relevant to both U.S. and global populations, ensuring broad applicability of their findings [21][22]